| Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial | |
| Zhou, Ai-Ping; Bai, Yuxian; Song, Yan; Luo, Hong; Ren, Xiu-Bao; Wang, Xiuwen; Shi, Benkang; Fu, Cheng; Cheng, Ying; Liu, Jiyan | |
| 2019 | |
| 卷号 | 24期号:8页码:E702-E708 |
| 关键词 | Anlotinib Metastatic renal cell cancer Phase II clinical trial |
| ISSN号 | 1083-7159 |
| DOI | 10.1634/theoncologist.2018-0839 |
| URL标识 | 查看原文 |
| 收录类别 | SCIE ; PUBMED |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/6343087 |
| 专题 | 中国医学科学院 北京协和医学院 |
| 推荐引用方式 GB/T 7714 | Zhou, Ai-Ping,Bai, Yuxian,Song, Yan,et al. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial[J],2019,24(8):E702-E708. |
| APA | Zhou, Ai-Ping.,Bai, Yuxian.,Song, Yan.,Luo, Hong.,Ren, Xiu-Bao.,...&Ma, Jianhui.(2019).Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.,24(8),E702-E708. |
| MLA | Zhou, Ai-Ping,et al."Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial".24.8(2019):E702-E708. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论